Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heart Failure | 12 | 2020 | 6638 | 1.13 | Why? |
| Space-Time Clustering | 1 | 2020 | 29 | 0.85 | Why? |
| Aminobutyrates | 2 | 2018 | 142 | 0.80 | Why? |
| Amiodarone | 1 | 2020 | 110 | 0.78 | Why? |
| Tetrazoles | 2 | 2018 | 262 | 0.72 | Why? |
| Anti-Arrhythmia Agents | 1 | 2020 | 325 | 0.69 | Why? |
| Natriuretic Peptides | 1 | 2016 | 66 | 0.59 | Why? |
| Physicians, Primary Care | 1 | 2016 | 298 | 0.47 | Why? |
| Thiazoles | 1 | 2016 | 496 | 0.46 | Why? |
| Pyridines | 1 | 2016 | 680 | 0.42 | Why? |
| Heart Rate | 2 | 2018 | 1527 | 0.40 | Why? |
| Cardiology | 5 | 2021 | 2873 | 0.39 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.39 | Why? |
| Stroke Volume | 2 | 2018 | 2153 | 0.37 | Why? |
| Hypoglycemic Agents | 2 | 2018 | 2165 | 0.36 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.35 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2018 | 6166 | 0.33 | Why? |
| Shock, Cardiogenic | 3 | 2017 | 700 | 0.32 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2018 | 3892 | 0.28 | Why? |
| Atrial Fibrillation | 2 | 2017 | 2320 | 0.25 | Why? |
| Heart-Assist Devices | 2 | 2020 | 812 | 0.21 | Why? |
| CCR5 Receptor Antagonists | 1 | 2020 | 66 | 0.21 | Why? |
| Valsartan | 2 | 2018 | 206 | 0.20 | Why? |
| Biphenyl Compounds | 2 | 2018 | 249 | 0.20 | Why? |
| Transitional Care | 1 | 2020 | 135 | 0.18 | Why? |
| Plasmapheresis | 1 | 2020 | 437 | 0.16 | Why? |
| Hemoperfusion | 1 | 2020 | 260 | 0.16 | Why? |
| Electrophysiologic Techniques, Cardiac | 1 | 2020 | 396 | 0.16 | Why? |
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 206 | 0.16 | Why? |
| Hemofiltration | 1 | 2017 | 155 | 0.15 | Why? |
| Pacemaker, Artificial | 1 | 2020 | 431 | 0.15 | Why? |
| Dabigatran | 1 | 2017 | 204 | 0.14 | Why? |
| Factor Xa Inhibitors | 2 | 2017 | 490 | 0.14 | Why? |
| Electric Countershock | 1 | 2017 | 284 | 0.14 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.14 | Why? |
| Patient Preference | 1 | 2021 | 750 | 0.14 | Why? |
| HIV Antibodies | 1 | 2020 | 776 | 0.13 | Why? |
| Noninvasive Ventilation | 2 | 2017 | 2329 | 0.13 | Why? |
| Catheterization, Peripheral | 1 | 2017 | 249 | 0.13 | Why? |
| Rare Diseases | 1 | 2017 | 373 | 0.13 | Why? |
| Algorithms | 3 | 2020 | 7346 | 0.13 | Why? |
| Plasma Exchange | 1 | 2020 | 763 | 0.13 | Why? |
| Rivaroxaban | 1 | 2017 | 467 | 0.13 | Why? |
| Patient Transfer | 1 | 2020 | 898 | 0.12 | Why? |
| Warfarin | 1 | 2017 | 402 | 0.12 | Why? |
| Administration, Oral | 2 | 2017 | 2340 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Cardiovascular Diseases | 4 | 2021 | 11497 | 0.12 | Why? |
| Hemodynamics | 2 | 2017 | 1562 | 0.12 | Why? |
| Cardiovascular Agents | 1 | 2018 | 663 | 0.12 | Why? |
| Heart Defects, Congenital | 1 | 2021 | 933 | 0.12 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.11 | Why? |
| Hypnotics and Sedatives | 1 | 2017 | 624 | 0.11 | Why? |
| Drug Combinations | 2 | 2018 | 3852 | 0.11 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.11 | Why? |
| Lung Injury | 1 | 2020 | 919 | 0.11 | Why? |
| Italy | 6 | 2021 | 38444 | 0.10 | Why? |
| Patient Care Management | 1 | 2021 | 1514 | 0.10 | Why? |
| Aspirin | 1 | 2018 | 1043 | 0.10 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.10 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.10 | Why? |
| Needs Assessment | 1 | 2020 | 2352 | 0.10 | Why? |
| Enzyme Inhibitors | 1 | 2020 | 1881 | 0.10 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.10 | Why? |
| Acute Coronary Syndrome | 2 | 2020 | 2107 | 0.09 | Why? |
| Positive-Pressure Respiration | 1 | 2017 | 1160 | 0.09 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2020 | 1322 | 0.09 | Why? |
| Ambulatory Care Facilities | 1 | 2020 | 2063 | 0.09 | Why? |
| Infection Control | 4 | 2021 | 23131 | 0.09 | Why? |
| Health Services Needs and Demand | 2 | 2020 | 3419 | 0.09 | Why? |
| Humans | 29 | 2021 | 930598 | 0.09 | Why? |
| Pandemics | 9 | 2020 | 389249 | 0.09 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.09 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2018 | 1671 | 0.08 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.08 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 9706 | 0.08 | Why? |
| Thromboembolism | 2 | 2017 | 2101 | 0.08 | Why? |
| Referral and Consultation | 2 | 2020 | 4816 | 0.08 | Why? |
| Drug Design | 1 | 2018 | 2627 | 0.08 | Why? |
| Arrhythmias, Cardiac | 1 | 2020 | 2510 | 0.08 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.08 | Why? |
| Decision Trees | 2 | 2017 | 441 | 0.07 | Why? |
| Continuity of Patient Care | 1 | 2016 | 1574 | 0.07 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.07 | Why? |
| Blood Glucose | 1 | 2018 | 3642 | 0.07 | Why? |
| Health Surveys | 1 | 2016 | 2841 | 0.07 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.07 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.07 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.06 | Why? |
| Clinical Trials as Topic | 2 | 2018 | 7330 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.06 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.06 | Why? |
| Aged | 7 | 2020 | 215776 | 0.05 | Why? |
| Telemedicine | 3 | 2021 | 25032 | 0.05 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2020 | 29620 | 0.05 | Why? |
| Predictive Value of Tests | 1 | 2016 | 9537 | 0.05 | Why? |
| Acute Disease | 3 | 2018 | 6029 | 0.05 | Why? |
| Role | 1 | 2020 | 266 | 0.05 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.05 | Why? |
| Coronary Care Units | 1 | 2020 | 224 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Blood Circulation | 1 | 2017 | 99 | 0.04 | Why? |
| Tranquilizing Agents | 1 | 2017 | 9 | 0.04 | Why? |
| Neprilysin | 1 | 2018 | 112 | 0.04 | Why? |
| Ultrafiltration | 1 | 2017 | 42 | 0.04 | Why? |
| Contraindications, Drug | 1 | 2018 | 281 | 0.04 | Why? |
| Prosthesis Implantation | 1 | 2020 | 261 | 0.04 | Why? |
| Narcotics | 1 | 2017 | 67 | 0.04 | Why? |
| Partial Pressure | 1 | 2017 | 279 | 0.04 | Why? |
| Stroke | 2 | 2017 | 8839 | 0.04 | Why? |
| Vascular Resistance | 1 | 2017 | 148 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Respiratory Physiological Phenomena | 1 | 2017 | 157 | 0.04 | Why? |
| Barotrauma | 1 | 2017 | 97 | 0.04 | Why? |
| Early Termination of Clinical Trials | 1 | 2018 | 1256 | 0.04 | Why? |
| Psychomotor Agitation | 1 | 2017 | 208 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Diuretics | 1 | 2017 | 326 | 0.04 | Why? |
| Hemorrhage | 2 | 2018 | 3013 | 0.04 | Why? |
| Hypotension | 1 | 2018 | 392 | 0.04 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2016 | 22971 | 0.03 | Why? |
| National Health Programs | 1 | 2021 | 807 | 0.03 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Antithrombins | 1 | 2017 | 353 | 0.03 | Why? |
| Prevalence | 1 | 2016 | 25773 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Body Fluids | 1 | 2017 | 451 | 0.03 | Why? |
| Analgesics | 1 | 2017 | 451 | 0.03 | Why? |
| Pulmonary Edema | 1 | 2017 | 430 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 8811 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.03 | Why? |
| Biomarkers | 1 | 2016 | 23361 | 0.03 | Why? |
| Oxygen Consumption | 1 | 2017 | 711 | 0.03 | Why? |
| Male | 7 | 2021 | 367725 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Checklist | 1 | 2017 | 714 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.03 | Why? |
| Stents | 1 | 2018 | 916 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2017 | 1289 | 0.03 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.03 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.02 | Why? |
| Animals | 1 | 2018 | 78931 | 0.02 | Why? |
| Patient Care | 1 | 2020 | 1664 | 0.02 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.02 | Why? |
| Continuous Positive Airway Pressure | 1 | 2017 | 1187 | 0.02 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.02 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.02 | Why? |
| Heart | 1 | 2017 | 1791 | 0.02 | Why? |
| Patient Compliance | 1 | 2017 | 1468 | 0.02 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Anticoagulants | 2 | 2017 | 9563 | 0.02 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.02 | Why? |
| Home Care Services | 1 | 2017 | 1351 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.02 | Why? |
| Female | 6 | 2021 | 380317 | 0.02 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2020 | 3051 | 0.02 | Why? |
| Oxygen | 1 | 2017 | 3715 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Percutaneous Coronary Intervention | 1 | 2018 | 3646 | 0.01 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.01 | Why? |
| Middle Aged | 2 | 2018 | 270681 | 0.01 | Why? |
| Triage | 1 | 2018 | 7151 | 0.01 | Why? |
| Registries | 1 | 2018 | 12327 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.01 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.01 | Why? |
| Respiratory Insufficiency | 1 | 2017 | 7301 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Hospital Mortality | 1 | 2018 | 22087 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Adult | 1 | 2021 | 244371 | 0.00 | Why? |
Aspromonte's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(191)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(70)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_